Global Structural Cardiac Implants Market Size By Type (Heart Valves And Accessories, Tissue Heart Valves), By Application (Hospitals, Ambulatory Settings), By Region, And Segment Forecasts, 2023 to 2...

The Global Structural Cardiac Implants Market was valued at USD 12.6 billion in 2023 and is projected to reach USD 24.5 billion by 2031, growing at a CAGR of 8.7% during the forecast period from 2023 to 2031. This market is being propelled by the rising prevalence of structural heart diseases, technological advancements in cardiac implants, and the growing preference for minimally invasive surgical procedures. Increasing geriatric population, favorable reimbursement scenarios, and a surge in awareness about early diagnosis and treatment of heart conditions further contribute to market expansion.

Drivers:

1. Growing Prevalence of Structural Heart Diseases:

Conditions such as aortic stenosis, atrial septal defects, and mitral valve regurgitation are becoming increasingly common, especially among the elderly. The rising need for treatment options that restore heart function is a significant driver.

2. Technological Advancements in Implant Materials and Design:

Innovations such as bioresorbable materials, 3D printing, and transcatheter implantation techniques have revolutionized the field, enhancing outcomes and reducing recovery times.

3. Minimally Invasive Procedures:

The shift towards catheter-based and non-surgical implantations has made structural cardiac procedures more accessible, safer, and less taxing on patients, boosting market adoption globally.

Restraints:

1. High Procedure Costs and Implant Pricing:

Despite improved outcomes, the high cost of structural cardiac implants and associated surgical procedures limits access, particularly in low- and middle-income regions.

2. Regulatory and Approval Challenges:

Lengthy and complex regulatory approval processes for novel implants can delay product launches and hinder market penetration, especially for small and mid-sized manufacturers.

Opportunity:

1. Emerging Markets with Untapped Potential:

Countries in Asia-Pacific and Latin America are witnessing improvements in healthcare infrastructure and increased investments in cardiac care, offering immense growth opportunities.

2. Rising Adoption of AI and Imaging Integration:

The integration of AI-driven imaging and diagnostics with structural implant procedures enhances precision and clinical outcomes, opening new avenues for innovation.

Market by System Type Insights:

Among the different types of structural cardiac implants, Transcatheter Aortic Valve Replacement (TAVR) dominated the market in 2023 due to its minimally invasive nature and strong clinical outcomes in high-risk patients. However, Transcatheter Mitral Valve Repair (TMVr) is expected to be the fastest-growing segment, driven by expanding indications and ongoing device development.

Market by End-use Insights:

Hospitals accounted for the largest market share in 2023, as they are the primary centers for advanced cardiovascular procedures. The cardiac specialty clinics segment is anticipated to witness robust growth due to increasing investments in specialized infrastructure and outpatient procedure models.

Market by Regional Insights:

North America led the global structural cardiac implants market in 2023, supported by high healthcare expenditure, rapid adoption of advanced devices, and strong reimbursement policies. Asia-Pacific, on the other hand, is expected to register the highest CAGR during the forecast period, with rising geriatric population, better access to healthcare services, and expanding government initiatives in cardiac care.

Competitive Scenario:

Key players in the global structural cardiac implants market include Medtronic plc, Edwards Lifesciences Corporation, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, JenaValve Technology, and CryoLife, Inc. These companies are focusing on strategic partnerships, R&D investments, and product launches to gain competitive advantages.

Key Developments:

In 2024, Abbott Laboratories launched the next-generation MitraClip system in Europe and the U.S., expanding its application to moderate-risk patients.

Medtronic received FDA approval in 2023 for its Evolut FX TAVR platform designed to improve valve placement accuracy.

In 2025, Edwards Lifesciences announced a $300 million expansion of its heart valve manufacturing facilities to meet growing global demand.

Scope of Work – Global Structural Cardiac Implants Market

Report Metric Details

Market Size (2023) USD 12.6 billion

Projected Market Size (2031) USD 24.5 billion

CAGR (2023–2031) 8.7%

Market Segments System Type (TAVR, TMVr, Others), End-Use, Region

Growth Drivers Aging population, technological innovation, minimally invasive procedures

Opportunities Emerging economies, AI and imaging integration

FAQs:

1) What is the current market size of the Global Structural Cardiac Implants Market?

The market was valued at USD 12.6 billion in 2023.

2) What is the major growth driver of the Global Structural Cardiac Implants Market?

The increasing prevalence of structural heart diseases and technological advancements in implants are major growth drivers.

3) Which is the largest region during the forecast period in the Global Structural Cardiac Implants Market?

North America holds the largest share due to its advanced healthcare system and reimbursement policies.

4) Which segment accounted for the largest market share in Global Structural Cardiac Implants Market?

Transcatheter Aortic Valve Replacement (TAVR) was the largest system type segment in 2023.

5) Who are the key market players in the Global Structural Cardiac Implants Market?

Major players include Medtronic, Edwards Lifesciences, Abbott, Boston Scientific, and LivaNova.